"When we launch, we'll go all in," Emil Kongshøj Larsen, Executive Vice President for International Operations at Novo Nordisk, told CNBC. The company said the Wegovy pill has reached more than 3 million prescriptions in the United States since its launch on 5 January, a volume the firm describes as roughly one prescription filled every five seconds. That surge helped produce $355 million in Wegovy pill sales in the first quarter and has drawn a large share of prescriptions from patients who had not previously used GLP-1 drugs. As rivals, insurers and telehealth platforms react, the early picture is of a market being widened more than simply divided.

"Our customers are excited about the Wegovy pill in particular," Bill Newby, a Hims & Health executive, said in May. That enthusiasm maps to a clear commercial advantage for Novo Nordisk: the company markets four oral Wegovy doses and internal commentary indicates a substantial portion of new prescriptions are true new users rather than switches from injectable GLP-1 therapies.

Launch momentum, then moderation

Prescription-tracking data show the Wegovy pill's early momentum remains robust but is beginning to moderate. IQVIA-tracked figures put Wegovy pill prescriptions at about 146,000 in the week ending 22 May, the twentieth week on market, with week-on-week growth of about 2 percent and a matching four-week rolling average. Those numbers represent a deceleration from the launch peak, yet they leave Wegovy pill prescribing at roughly 2.4 times the volume that Lilly's injectable Zepbound achieved at the same stage.

By contrast, Eli Lilly's oral entrant Foundayo has recorded far fewer prescriptions in comparable early weeks. IQVIA tallies put Foundayo at roughly 16,000 prescriptions in its sixth full week on the market and about 17,000 by its eighth week in other counts. Lilly told investors on 30 April that more than 20,000 people had started Foundayo since its April launch. Analysts and pharmacy-benefit managers point to slower private-insurance coverage for Foundayo and the timing of direct-to-consumer marketing as explanations for its more muted uptake.

Citi has noted that television direct-to-consumer advertising for Foundayo isn't scheduled to begin until the third quarter, a delay that may hold back mass-market awareness until later in the year. Novo Nordisk, meanwhile, said it plans the first launches of the Wegovy pill outside the United States later this year, pending regulatory approvals.

Mastheads

How the pills are changing who seeks treatment

Market observers and bank analysts have flagged two commercial dynamics. First, the oral pills are generally less potent than the weekly injections. Second, their lower cost and simpler dosing make them attractive to younger and male patients and to people who want maintenance therapy after injection-induced weight loss.

That combination is precisely why telehealth platforms and lower-cost providers have seen new demand coming from people who were not previously GLP-1 users.

Telehealth has already broadened access in some markets, Novo Nordisk said, citing Germany as an example. Pharmacy-benefit managers have begun adding oral GLP-1 options to formularies, which could alter uptake patterns materially as private coverage expands. Hims & Health's Bill Newby framed the shift plainly: the Wegovy pill is drawing interest from lower-cost seekers as well as new users.

Nordea analysts have gone further in their read of demand, using Google Trends and prescription metrics to conclude that Wegovy is becoming the leading household weight-loss brand in the United States. That brand momentum helps explain why Novo continues to promote an aggressive commercial push. Still, the company has warned of broader pressures on its top line in 2026 because of lower U.S. prices and expected generic competition in several markets, a reminder that launch success doesn't erase larger margin and pricing dynamics.

For competitors such as Lilly, the path is one of staged commercial moves. Foundayo's early numbers suggest slower adoption than Novo's oral offering, and banks and analysts expect marketing cadence to matter: Citi expects television advertising for Foundayo to start in the third quarter, a move that may accelerate uptake if it reaches a broader audience than initial channels did.

The commercial picture is therefore twofold. On one hand, oral GLP-1 pills are expanding the pool of potential patients, changing the demographic mix of users and prompting telehealth and PBMs to adjust. On the other hand, incumbents and new entrants must still contend with pricing pressure, coverage hurdles and the strategic choices around when and how to advertise to a mass market.

That combination explains both the excitement inside the sector and the caution in corporate forecasts. The Wegovy pill has electrified a market and created real momentum, but Novo Nordisk itself expects sales and profits to decline in 2026 within a range centred on its guidance, reflecting the longer term commercial and pricing environment.

Related Articles

Watch two near-term markers: when Foundayo moves into television advertising in the third quarter, and whether Novo Nordisk secures regulatory clearance to begin Wegovy pill launches outside the United States later this year. Originally reported by CNBC.

This article was created with AI assistance.